CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
azacitidine for injectable suspensiondrug
Likely dose
azacitidine for injectable suspension 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00384839
NCT00384839Phase 2Completed
CompareCT.gov

Phase II Study for the Use of Vidaza™ to Restore Responsiveness of Patients' Prostate Cancers to Hormonal Therapy

US Oncology Research·interventional·Posted Oct 6, 2006·Updated Oct 25, 2018

In Brief

A Phase 2 clinical trial evaluating azacitidine for injectable suspension for Prostate Cancer. Completed, enrolled 36 participants across 13 sites.

Detailed Summary

The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of prostate cancer; however, it is approved in myelodysplastic syndrome - a bone marrow disease. The pharmaceutical company involved in this study, Pharmion Corporation, is the manufacturer of Vidaza.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsCelgene Corporation, University of Southern California

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 6, 2006
Enrollment StartApr 1, 2006
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 19.7 years ago

Interventions

azacitidine for injectable suspensiondrug

Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.